ClinicalTrials.gg
RecruitingNCT07744802Updated Nov 6, 2026

Evaluate the Effect of Vimseltinib on P-glycoprotein (P-gp) Inhibition in Healthy Male Participants

A Phase 1 interventional study of Vimseltinib and Dabigatran in Healthy Male Participants, sponsored by Deciphera Pharmaceuticals, LLC. Recruiting at 1 site in United States. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Deciphera Pharmaceuticals, LLC (part of Ono Pharmaceutical Co. Ltd) · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Nov 6, 2026Now RecruitingFirst site in United States+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

The main purpose of this study is to determine the effect of vimseltinib on pharmacokinetics of P-glycoprotein (P-gp) substrate (dabigatran) in healthy male participants. This study will last approximately 21 days.

02

Conditions studied

  • Healthy Male Participants
03

In context

Lead sponsor

Deciphera Pharmaceuticals, LLC is the lead sponsor of 24 studies on the registry; 5 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 3 (30%) have results posted.

First submitted after Deciphera Pharmaceuticals, LLC became part of Ono Pharmaceutical Co. Ltd.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants are in good general health, as required by the protocol and as determined by Principal Investigator.
  2. (BMI) from greater than or equal to (≥) 18 to less than or equal to ≤ 32 kilogram per square meter (kg/m\^2).
  3. Adequate organ function and blood and urine tests, as required by the protocol and as determined by Principal Investigator.

Exclusion criteria

Exclusion Criteria:

  1. History or presence of diseases of the neurological, dermatological, renal, hepatic, gastrointestinal, cardiovascular, or musculoskeletal systems or history or presence of clinically significant psychiatric, immunological, endocrine, or metabolic disease as determined by Principal Investigator.
  2. Unwilling or unable to comply with the requirements of the protocol.
  3. Determined by Principal Investigator to be unsuitable to participate in the study for any other reason.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Vimseltinib + Dabigatran

    Day 1 single dose of dabigatran, and Day 5 coadministration of dabigatran with vimseltinib.

    Drug: Vimseltinib · Drug: Dabigatran

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Maximum Observed Plasma Drug Concentration (Cmax) of Dabigatran

    Time frame: Predose up to 48 Hours Post Dose

  2. PK: Area Under the Plasma Concentration-Time Curve from Time 0 up to Time t (AUC0-t), Where t is the Last Time Point at Which the Concentration is Above the Lower Limit of Quantification of Dabigatran

    Time frame: Predose up to 48 Hours Post Dose

  3. PK: AUC from Time 0 to Infinity (AUC0-∞) of Dabigatran

    Time frame: Predose up to 48 Hours Post Dose

Secondary outcomes

  1. Safety: Number of Participants with Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    Time frame: Baseline through Day 21

  2. Safety: Number of Participants with Clinically Significant Change from Baseline in Clinical Laboratory Parameters

    Time frame: Baseline through Day 21

  3. Safety: Number of Participants with Clinically Significant Change from Baseline in Vital Signs

    Time frame: Baseline through Day 21

  4. PK: Apparent Systemic Clearance (CL/F) of Dabigatran

    Time frame: Predose up to 48 Hours Post Dose

  5. PK: Apparent Volume of Distribution Associated with the Terminal Phase (Vz/F) of Dabigatran

    Time frame: Predose up to 48 Hours Post Dose

  6. PK: Time to Maximum Observed Plasma Concentration (Tmax) of Dabigatran

    Time frame: Predose up to 48 Hours Post Dose

  7. PK: Terminal Elimination Phase Half-Life (t1/2) of Dabigatran

    Time frame: Predose up to 48 Hours Post Dose

07

Study locations

1 of 1 sites recruiting
  • Dr. Vince Clinical Research
    Overland Park, Kansas 66212, United States
    Recruiting
    • · Contact913-333-3000
    • Benjamin T Sundling, D.O. · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Oct 2026 (actual). Primary completion is estimated for Dec 2026, 2 months after the start.

Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Oct 2026, on Nov 6, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2026
First posted
Aug 4, 2026
StartActual
Oct 8, 2026was Sep 2026
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Sep 25, 2026
Sites
1 site added — first site in United States
Show site
  • Dr. Vince Clinical Research · Overland Park, United States
Sep 25, 2026
Start date
Sep 2026→Oct 8, 2026 (actual)
Nov 6, 2026
Show all 2 updates
  1. Nov 6, 2026
    Start date Sep 2026→Oct 8, 2026 (now actual)
    + 1 other change: verification date
  2. Sep 25, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in United States
    Show site
    • Dr. Vince Clinical Research · Overland Park, United States

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07744802
Responsible party
Sponsor
First posted
Aug 4, 2026
Start date
Oct 8, 2026
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Nov 6, 2026

Study contacts

Clinical Team
Contact
clinicaltrials@deciphera.com
888-724-3274
Clinical Team
study director · Deciphera Pharmaceuticals, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vimseltinib

Start the discussion